Braveheart Bio (NASDAQ:BRVE) Major Shareholder Growth Opportunities Forbion Buys 1,920,000 Shares

Braveheart Bio, Inc. (NASDAQ:BRVE) major shareholder Growth Opportunities Forbion acquired 1,920,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $34,560,000.00. Following the acquisition, the insider owned 11,640,546 shares in the company, valued at approximately $209,529,828. The trade was a 19.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Braveheart Bio Stock Performance

BRVE traded up $0.20 during midday trading on Friday, hitting $30.00. The company had a trading volume of 566,582 shares. Braveheart Bio, Inc. has a twelve month low of $28.47 and a twelve month high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.